Published in World J Surg on September 01, 2004
Blood transcript analysis and metastatic recurrent small bowel carcinoid management. BMC Cancer (2014) 0.77
The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. Cancer Res Treat (2015) 0.75
Primary carcinoid tumor of medulla spinalis: case report and review of the literature. Eur J Med Res (2014) 0.75
The chromogranin-secretogranin family. N Engl J Med (2003) 4.28
Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg (2000) 2.60
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology (1993) 2.29
Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg (1998) 1.83
Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg (1995) 1.82
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Tumor markers in neuroendocrine tumors. Digestion (2000) 1.38
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab (1997) 1.38
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum. Regul Pept (1983) 1.22
Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol (1995) 1.18
Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology (2000) 1.05
Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg (1996) 0.95
The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res (2000) 0.88
Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery (1998) 0.82
Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg (2002) 0.82
Treatment of small intestinal neuroendocrine tumors: is an extended multimodal approach justified? World J Surg (2002) 0.80
Rapid, high-yield isolation of human chromogranin A from chromaffin granules of pheochromocytomas. Neuropeptides (1992) 0.80
Plasma levels of chromogranin A are directly proportional to tumour burden in neuroblastoma. J Endocrinol (1996) 0.78
Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. Eur J Gastroenterol Hepatol (1996) 0.75
[Estrogen and the heart]. Tidsskr Nor Laegeforen (2013) 2.03
Adiponectin and its receptors are expressed in bone-forming cells. Bone (2004) 1.86
Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem (2002) 1.49
Improved lymph node harvest from resected colon cancer specimens did not cause upstaging from TNM stage II to III. World J Surg (2011) 1.47
Cortical hand bone porosity and its association with distal radius fracture in middle aged and elderly women. PLoS One (2013) 1.47
Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res (2005) 1.33
Long-term serotonin administration induces heart valve disease in rats. Circulation (2005) 1.32
Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res (2009) 1.29
Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Mod Pathol (2007) 1.23
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol (2009) 1.19
Acute occlusion of the left subclavian artery causing a non-ST-elevation myocardial infarction with subacute lung edema due to a coronary subclavian steal syndrome--a case report. Int J Cardiol (2006) 1.15
Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem (2006) 1.14
Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat (2008) 1.12
The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol (2011) 1.06
Is aspect ratio a reliable predictor of intracranial aneurysm rupture? Neurosurgery (2004) 1.06
Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol (2010) 1.03
Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med (2003) 1.03
Benign peritoneal cystic mesothelioma. World J Surg (2006) 1.03
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord (2011) 1.01
Increased circulating hepatocyte growth factor (HGF): a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecol Oncol (2011) 1.00
Epidemiology of gastrointestinal stromal tumours: single-institution experience and clinical presentation over three decades. Cancer Epidemiol (2011) 0.99
[Appendiceal mucinous cystadenoma]. Tidsskr Nor Laegeforen (2005) 0.99
Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol (2011) 0.98
Arteriovenous malformation as a consequence of a scar pregnancy. Acta Obstet Gynecol Scand (2009) 0.97
Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem (2006) 0.97
Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am Heart J (2006) 0.96
Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol (2008) 0.96
Ten years' experience with centralized surgery of ovarian cancer in one health region in Norway. Int J Gynecol Cancer (2012) 0.95
Ameloblastin promotes bone growth by enhancing proliferation of progenitor cells and by stimulating immunoregulators. Eur J Oral Sci (2010) 0.95
Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol (2010) 0.93
Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age. Breast Cancer Res Treat (2008) 0.93
Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol (2009) 0.92
Mechanism of gastric bypass-induced body weight loss: one-year follow-up after micro-gastric bypass in rats. J Gastrointest Surg (2006) 0.91
Maximal strength training in postmenopausal women with osteoporosis or osteopenia. J Strength Cond Res (2013) 0.90
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One (2013) 0.90
LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol (2009) 0.89
The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3. J Clin Pathol (2011) 0.89
Cervical intraepithelial neoplasia grade 3 lesions can regress. APMIS (2007) 0.88
Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers. PLoS One (2012) 0.88
The ability of hand digital X-ray radiogrammetry to identify middle-aged and elderly women with reduced bone density, as assessed by femoral neck dual-energy X-ray absorptiometry. J Clin Densitom (2010) 0.88
In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol (2010) 0.87
Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol (2008) 0.87
Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome. Clin Transl Oncol (2012) 0.86
Evaluation of 5 different labeled polymer immunohistochemical detection systems. Appl Immunohistochem Mol Morphol (2010) 0.85
Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol (2012) 0.85
Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis (2008) 0.84
Extracellular N-acetylaspartate depletion in traumatic brain injury. J Neurochem (2005) 0.84
The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer. Cell Oncol (2009) 0.84
Maximal strength training improves bone mineral density and neuromuscular performance in young adult women. J Strength Cond Res (2014) 0.83
Long-term therapy in COPD: any evidence of adverse effect on bone? Int J Chron Obstruct Pulmon Dis (2009) 0.83
Expression of chromogranin A and somatostatin receptors in pancreatic AR42J cells. Mol Cell Endocrinol (2002) 0.83
The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer (2006) 0.83
Prognostic indicators in WHO 2003 low-grade endometrial stromal sarcoma. Histopathology (2013) 0.83
The cellular localization of the cholecystokinin 2 (gastrin) receptor in the stomach. Pharmacol Toxicol (2002) 0.83
Discrimination of grade 2 and 3 cervical intraepithelial neoplasia by means of analysis of water soluble proteins recovered from cervical biopsies. Proteome Sci (2011) 0.82
A protein profile study to discriminate CIN lesions from normal cervical epithelium. Cell Oncol (Dordr) (2011) 0.81
The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer. Breast Cancer Res Treat (2012) 0.81
Systemic leptin administration in supraphysiological doses maintains bone mineral density and mechanical strength despite significant weight loss. Endocrinology (2012) 0.80
The prognostic value of the orphan nuclear receptor DAX-1 (NROB1) in node-negative breast cancer. Anticancer Res (2011) 0.80
Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol (2011) 0.80
Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol (2010) 0.80
Decreased bone mineral density and reduced bone quality in H(+) /K(+) ATPase beta-subunit deficient mice. J Cell Biochem (2012) 0.80
A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol (2010) 0.80
Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. Hum Pathol (2008) 0.79
Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients. Acta Oncol (2009) 0.79
Cell-cycle and apoptosis regulators (p16INK4A, p21CIP1, beta-catenin, survivin, and hTERT) and morphometry-defined MPECs predict metachronous cancer development in colorectal adenoma patients. Cell Oncol (2007) 0.79
Phalangeal densitometry compared with dual energy X-ray absorptiometry for assessment of bone mineral density in elderly women. J Womens Health (Larchmt) (2011) 0.79
Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol (2011) 0.78
Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade? PLoS One (2013) 0.78
The total number of lymph nodes in resected colon cancer specimens is affected by several factors but the lymph node ratio is independent of these. APMIS (2013) 0.78
Surgery for gastrointestinal stromal tumors (GISTs) of the stomach and small bowel: short- and long-term outcomes over three decades. World J Surg (2015) 0.78
Acute endovascular repair of right subclavian arterial perforation from clavicular fracture after blunt trauma. J Vasc Interv Radiol (2007) 0.78
Biomechanical femoral neck fracture experiments--a narrative review. Injury (2012) 0.78
The prognostic value of molecular biomarkers in tissue removed by curettage from FIGO stage 1 and 2 endometrioid type endometrial cancer. Am J Obstet Gynecol (2008) 0.78
Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer. Breast Cancer Res Treat (2008) 0.78
Consistent condom use increases spontaneous regression in high-risk non-HPV16 but not in HPV16 CIN2-3 lesions, a prospective population-based cohort study. Infect Agent Cancer (2012) 0.78
Consistent condom use increases the regression rate of cervical intraepithelial neoplasia 2-3. PLoS One (2012) 0.77
Prognostic value of the diagnostic criteria distinguishing endometrial stromal sarcoma, low grade from undifferentiated endometrial sarcoma, 2 entities within the invasive endometrial stromal neoplasia family. Int J Gynecol Pathol (2013) 0.77
High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Anal Cell Pathol (Amst) (2010) 0.77
High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Cell Oncol (Dordr) (2011) 0.77
Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Arch Osteoporos (2015) 0.77
Enamel matrix derivative stimulates expression and secretion of resistin in mesenchymal cells. Eur J Oral Sci (2011) 0.76
Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal Quant Cytol Histol (2004) 0.76
Hypothalamic gene expression following ghrelin therapy to gastrectomized rodents. Regul Pept (2007) 0.76
Serotonin and fluoxetine receptors are expressed in enamel organs and LS8 cells and modulate gene expression in LS8 cells. Eur J Oral Sci (2010) 0.76
Nimodipine for traumatic [corrected] subarachnoid haemorrhage: the end of the road or better trials? Lancet Neurol (2006) 0.75
Skeletal effects of the saturated 3-thia Fatty Acid tetradecylthioacetic Acid in rats. PPAR Res (2011) 0.75
Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. Hum Pathol (2008) 0.75
Medicinal prevention of pre-diabetes--no purpose? Tidsskr Nor Laegeforen (2011) 0.75
Tidsskr Nor Laegeforen (2017) 0.75
Comparison of apolipoprotein D determination methods in breast cancer. Anticancer Res (2008) 0.75
[Palliative surgery in cancer care]. Tidsskr Nor Laegeforen (2007) 0.75
Diagnostic and prognostic morphometric features in WHO2003 invasive endometrial stromal tumours. Histopathology (2013) 0.75